TY - JOUR
T1 - Ruxolitinib
T2 - A steroid sparing agent in chronic graft-versus-host disease
AU - Khoury, Hanna Jean
AU - Langston, Amelia A.
AU - Kota, Vamsi K.
AU - Wilkinson, Jennifer A.
AU - Pusic, Iskra
AU - Jillella, Anand
AU - Bauer, Stephanie
AU - Kim, Audrey S.
AU - Roberts, Danielle
AU - Al-Kadhimi, Zaid
AU - Bodo, Imre
AU - Winton, Elliott
AU - Arellano, Martha
AU - Dipersio, John F.
N1 - Funding Information:
Author contributions HJK and JFD: designed research, performed research, collected data, provided subjects, analyzed and interpreted data, performed statistical analysis, wrote the manuscript; VKK, AAL, IP, AJ, EW, DR, ZAK, IB, and MA performed research, collected data, provided subjects, analyzed and interpreted data, reviewed and approved the manuscript; JW, SB, and ASK: collected data, analyzed and interpreted data, reviewed, and approved the manuscript. JFD is supported by the National Cancer Institute (NIH/NCI: R35 CA210084 and P50 CA171963.
Publisher Copyright:
© 2018 Macmillan Publishers Limited, part of Springer Nature.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.
AB - Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.
UR - http://www.scopus.com/inward/record.url?scp=85040911317&partnerID=8YFLogxK
U2 - 10.1038/s41409-017-0081-5
DO - 10.1038/s41409-017-0081-5
M3 - Article
C2 - 29367708
AN - SCOPUS:85040911317
SN - 0268-3369
VL - 53
SP - 826
EP - 831
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 7
ER -